-
1
-
-
0013401756
-
-
National Cancer Institute based on November 2011 SEER data submission, posted to the SEER web site, April 2012
-
National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets. 2009. http://seer.cancer.gov/csr/1975-2009-pops09, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
-
(2009)
Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets
-
-
-
2
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
17287242 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D
-
Ferlay J, Autier P, Boniol M, Heanue M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-92.
-
(2007)
Ann Oncol
, vol.18
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
-
3
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
9196156 1:CAS:528:DyaK2sXlsFKksLY%3D
-
Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
-
4
-
-
14844320515
-
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study
-
Hellenic Oncology Research Group et al. 10.1081/CNV-46502
-
Androulakis N, Syrigosk, Polyzos A, Hellenic Oncology Research Group, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005;93:9-12.
-
(2005)
Cancer Invest
, vol.93
, pp. 9-12
-
-
Androulakis, N.1
Syrigosk2
Polyzos, A.3
-
5
-
-
0043132277
-
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer
-
12860947 10.1200/JCO.2003.02.071 1:CAS:528:DC%2BD2cXptlCktLc%3D
-
Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol. 2003;21(14):2703-7.
-
(2003)
J Clin Oncol
, vol.21
, Issue.14
, pp. 2703-2707
-
-
Hochster, H.1
Chachoua, A.2
Speyer, J.3
-
6
-
-
0141959357
-
Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: Preliminary results
-
Guarneri D, Venturino A, Addamo G. Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: preliminary results. Ann Oncol. 2002;13 Suppl 5:87.
-
(2002)
Ann Oncol
, vol.13
, Issue.SUPPL. 5
, pp. 87
-
-
Guarneri, D.1
Venturino, A.2
Addamo, G.3
-
7
-
-
0037093207
-
Bolus fluorouracil and leucovorin with oxaliplatin as first line treatment in metastatic colorectal cancer
-
12011134 10.1200/JCO.2002.08.144 1:CAS:528:DC%2BD38XksFaku74%3D
-
Ravaioli A, Marangolo M, Pasqiuni E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first line treatment in metastatic colorectal cancer. J Clin Oncol. 2002;20(10):2545-50.
-
(2002)
J Clin Oncol
, vol.20
, Issue.10
, pp. 2545-2550
-
-
Ravaioli, A.1
Marangolo, M.2
Pasqiuni, E.3
-
8
-
-
57849117384
-
New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)
-
10.1016/j.ejca.2008.10.026
-
Eisenhaurer EA, Therasse P, Borgaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhaurer, E.A.1
Therasse, P.2
Borgaerts, J.3
-
9
-
-
10744228140
-
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
-
12903007 10.1016/S1053-4296(03)00031-6
-
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81.
-
(2003)
Semin Radiat Oncol
, vol.13
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
-
10
-
-
0036796596
-
Oxaliplatin: Results in colorectal carcinoma
-
12398998 10.1016/S1040-8428(01)00192-5
-
Carrato A, Gallego J, Diaz-Rubio E. Oxaliplatin: results in colorectal carcinoma. Crit Rev Oncol Hematol. 2002;44(1):29-44.
-
(2002)
Crit Rev Oncol Hematol
, vol.44
, Issue.1
, pp. 29-44
-
-
Carrato, A.1
Gallego, J.2
Diaz-Rubio, E.3
-
11
-
-
0037068330
-
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
-
12177775 10.1038/sj.bjc.6600467 1:CAS:528:DC%2BD38XmtVOntbY%3D
-
Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87(4):393-9.
-
(2002)
Br J Cancer
, vol.87
, Issue.4
, pp. 393-399
-
-
Cheeseman, S.L.1
Joel, S.P.2
Chester, J.D.3
-
13
-
-
22144433634
-
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
-
16012797 10.1007/s10637-005-1446-y 1:CAS:528:DC%2BD2MXmtVymtb4%3D
-
Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005;23:369-75.
-
(2005)
Invest New Drugs
, vol.23
, pp. 369-375
-
-
Tsavaris, N.1
Kosmas, C.2
Skopelitis, H.3
-
14
-
-
67650275306
-
A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings
-
Schrag D, Archer L, Wang X, et al. A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25(Suppl pt 1):4524.
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.
, pp. 4524
-
-
Schrag, D.1
Archer, L.2
Wang, X.3
-
15
-
-
48949087810
-
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
-
10.1200/JCO.2008.16.7528
-
Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol. 2008;26:A4058.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4058
-
-
Pelzer, U.1
Kubica, K.2
Stieler, J.3
-
16
-
-
84859089062
-
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
-
22493549 10.3748/wjg.v18.i12.1357 1:CAS:528:DC%2BC38Xls1Gis7s%3D
-
Altwegg R, Ychou M, Guillaumon V, et al. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol. 2012;18(12):1357-64.
-
(2012)
World J Gastroenterol
, vol.18
, Issue.12
, pp. 1357-1364
-
-
Altwegg, R.1
Ychou, M.2
Guillaumon, V.3
-
17
-
-
8344288331
-
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
-
15539911 10.1159/000080993 1:CAS:528:DC%2BD2cXpslWit70%3D
-
Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93-7.
-
(2004)
Oncology
, vol.67
, pp. 93-97
-
-
Cantore, M.1
Rabbi, C.2
Fiorentini, G.3
-
18
-
-
18744366016
-
Gemcitabine and oxaliplatin in gemcitabine-refractory advanced pancreatic cancer: A phase II study
-
Van Laethem JL, Polus M, Marechal R, et al. Gemcitabine and oxaliplatin in gemcitabine-refractory advanced pancreatic cancer: a phase II study. Proc Am Soc Clin Oncol. 2004;23:4119.
-
(2004)
Proc Am Soc Clin Oncol
, vol.23
, pp. 4119
-
-
Van Laethem, J.L.1
Polus, M.2
Marechal, R.3
-
19
-
-
19944427916
-
Salvage chemotherapy with mitomycin, docetaxel and irinotecan in metastatic pancreatic adenocarcinoma: A phase i and II trial
-
15581049 10.1081/CNV-200032929 1:CAS:528:DC%2BD2cXosFSiu7Y%3D
-
Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel and irinotecan in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest. 2004;22:688-96.
-
(2004)
Cancer Invest
, vol.22
, pp. 688-696
-
-
Reni, M.1
Panucci, M.G.2
Passoni, P.3
-
20
-
-
3042524200
-
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic cancer
-
15221998 10.1002/cncr.20338 1:CAS:528:DC%2BD2cXlvFCmsr0%3D
-
Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic cancer. Cancer. 2004;101:133-8.
-
(2004)
Cancer
, vol.101
, pp. 133-138
-
-
Milella, M.1
Gelibter, A.2
Di Cosimo, S.3
-
21
-
-
63849329062
-
Second-line therapy in refractory pancreatic cancer. Results of a phase II study
-
19295247 10.1159/000197769 1:CAS:528:DC%2BD1MXjtlOlsrs%3D
-
Pelzer U, Stieler J, Roll L, et al. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkologie. 2009;32:99-102.
-
(2009)
Onkologie
, vol.32
, pp. 99-102
-
-
Pelzer, U.1
Stieler, J.2
Roll, L.3
-
22
-
-
39549120238
-
The role of second-line chemotherapy for gemcitabine failure in patients with advanced pancreatic cancer
-
18240999 10.2217/14796694.4.1.41 1:CAS:528:DC%2BD1cXhslehs7g%3D
-
Boeck S, Heinemann V. The role of second-line chemotherapy for gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008;4:41-50.
-
(2008)
Future Oncol
, vol.4
, pp. 41-50
-
-
Boeck, S.1
Heinemann, V.2
-
23
-
-
34548241874
-
Shh signaling and pancreatic cancer: Implications for therapy?
-
17611415 10.4161/cc.6.13.4467 1:CAS:528:DC%2BD2sXhtFWlsrzK
-
Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle. 2007;6:1553-7.
-
(2007)
Cell Cycle
, vol.6
, pp. 1553-1557
-
-
Morton, J.P.1
Lewis, B.C.2
-
24
-
-
74949135901
-
Targeting Notch signaling in pancreatic cancer patients - Rationale for new therapy
-
Mysliviec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients - rationale for new therapy. Adv Med Sci. 2009;54:136-42.
-
(2009)
Adv Med Sci
, vol.54
, pp. 136-142
-
-
Mysliviec, P.1
Boucher, M.J.2
|